Antibiotics Companies

Entasis Therapeutics (US) receives FDA Fast Track designation for its investigational antibiotic ETX2006 for the treatment of multi-drug resistant (MDR) Gram-negative bacterial infections.

Spero Therapeutics (US) announces positive phase 3 trial results for its antibiotic SPR720 for the treatment of community-acquired bacterial pneumonia (CABP).

Me antibiotics (UK) and Evotec SE (Germany) collaborate to develop novel antibiotics targeting Gram-negative bacteria, leveraging Evotec's AI-powered platform.

Merck KGaA (Germany) partners with MIT to develop new antifungal drug candidates using machine learning algorithms and advanced screening techniques.

• Pfizer Inc. (US)   


• Johnson & Johnson Services, Inc. (US)  


• Abbott Laboratories (US)   


• GlaxoSmithKline PLC (UK)


• Sanofi (France)


• Novartis AG (Switzerland)


• Bayer AG (Germany)   


• Bristol-Myers Squibb Company (US)


• Eli Lilly and Company (US)


• Astellas Pharma Inc. (Japan)    


• Merck & Co., Inc. (US)


•  F. Hoffmann-La Roche Ltd (Switzerland)